Skip to main content
Fig. 5 | BMC Gastroenterology

Fig. 5

From: ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma

Fig. 5

ARID1A deficiency was associated with elevated immune checkpoint expression and upregulated Galectin-9 expression. a ARID1A deficiency has significantly higher expression levels of the immune checkpoint. b ARID1A knockdown by siRNA in HepG2/2.2.15 cell line was confirmed by Western blotting. c EZH2 and galectin-9 mRNA levels were measured after ARID1A knockout or knockdown (n = 3). d, e Representative flow cytometric analysis showing galectin-9-positive cells in Hep3B and HepG2/2.215 cells. f Immunohistochemical staining for TIM3 expression within patients carry ARID1A mutation or not. Scale bar = 100 μm or 50 μm. (* P < 0.05, ** P < 0.01, *** P < 0.001)

Back to article page